BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24943349)

  • 1. Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.
    Shanmugam V; Ramanathan RK; Lavender NA; Sinari S; Chadha M; Liang WS; Kurdoglu A; Izatt T; Christoforides A; Benson H; Phillips L; Baker A; Murray C; Hostetter G; Von Hoff DD; Craig DW; Carpten JD
    BMC Med Genomics; 2014 Jun; 7():36. PubMed ID: 24943349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
    Brannon AR; Vakiani E; Sylvester BE; Scott SN; McDermott G; Shah RH; Kania K; Viale A; Oschwald DM; Vacic V; Emde AK; Cercek A; Yaeger R; Kemeny NE; Saltz LB; Shia J; D'Angelica MI; Weiser MR; Solit DB; Berger MF
    Genome Biol; 2014 Aug; 15(8):454. PubMed ID: 25164765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
    PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel mutations by exome sequencing in African American colorectal cancer patients.
    Ashktorab H; Daremipouran M; Devaney J; Varma S; Rahi H; Lee E; Shokrani B; Schwartz R; Nickerson ML; Brim H
    Cancer; 2015 Jan; 121(1):34-42. PubMed ID: 25250560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
    Winder T; Zhang W; Yang D; Ning Y; Bohanes P; Gerger A; Wilson PM; Pohl A; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2010 Nov; 16(22):5591-602. PubMed ID: 20935157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
    Bozzao C; Varvara D; Piglionica M; Bagnulo R; Forte G; Patruno M; Russo S; Piscitelli D; Stella A; Resta N
    Int J Biol Markers; 2012 Dec; 27(4):e366-74. PubMed ID: 23125007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
    Zhu K; Yan H; Wang R; Zhu H; Meng X; Xu X; Dou X; Chen D
    Med Oncol; 2014 Jul; 31(7):16. PubMed ID: 24861917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
    Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
    PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
    Mekenkamp LJ; Tol J; Dijkstra JR; de Krijger I; Vink-Börger ME; van Vliet S; Teerenstra S; Kamping E; Verwiel E; Koopman M; Meijer GA; van Krieken JH; Kuiper R; Punt CJ; Nagtegaal ID
    BMC Cancer; 2012 Jul; 12():292. PubMed ID: 22804917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
    Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
    Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
    Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
    Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.